Tag Archive for: peptides vs small-molecule drugs

Peptides vs Classic Small-Molecule Drugs: A Researcher’s Guide Using Prednisone, Atorvastatin, and Spironolactone as Case Studies

Peptides vs Classic Small-Molecule Drugs: A Researcher’s Guide Using Prednisone, Atorvastatin, and Spironolactone as Case Studies

/0 Comments/in /by

More than 80 approved peptide therapeutics were on the global market by 2026, a figure that has more than doubled over the past decade, yet small-molecule drugs still account for roughly 90% of all oral prescriptions worldwide. That tension sits at the heart of modern pharmacology, and it makes the comparison of Peptides vs Classic Small-Molecule Drugs: A Researcher's Guide Using Prednisone, Atorvastatin, and Spironolactone as Case Studies especially timely for laboratory scientists designing mechanistic studies or evaluating research compounds.

Key Takeaways

  • Small molecules such as prednisone, atorvastatin, and spironolactone achieve oral bioavailability through low molecular weight and lipophilicity, but carry pleiotropic off-target risks.
  • Peptides offer high receptor selectivity and a favorable safety profile, at the cost of proteolytic instability and limited oral delivery.
  • Each drug class occupies distinct chemical space; understanding those boundaries sharpens study design.
  • AI-driven molecular design is accelerating peptide optimization, narrowing the gap with small-molecule drug-likeness.
  • Researchers in 2026 increasingly design hybrid protocols that leverage both modalities rather than treating them as mutually exclusive.

Understanding the Chemical Divide

Understanding the Chemical Divide

The core difference between peptides and classic small molecules is size. Small-molecule drugs typically fall below 500 daltons (Da), a threshold often called Lipinski's rule of five, which allows passive diffusion across cell membranes and supports oral dosing. Peptides, built from amino-acid chains, generally exceed 500 Da and fold into three-dimensional conformations that confer exquisite receptor complementarity.

Key physicochemical contrasts:

Property Small Molecules Peptides
Molecular weight <500 Da 500-5,000+ Da
Oral bioavailability High (many) Low without modification
Primary metabolism CYP450 enzymes Proteolytic degradation
Receptor selectivity Moderate High
Off-target burden Often significant Generally lower

This table is not a verdict, it is a map. Researchers who understand peptide structure, mechanisms, and receptor-level pharmacology can use that map to choose the right tool for each experimental question.

Three Small-Molecule Case Studies: Prednisone, Atorvastatin, and Spironolactone

Three Small-Molecule Case Studies: Prednisone, Atorvastatin, and Spironolactone

These three drugs dominate global prescription volumes and represent three distinct mechanistic archetypes, making them ideal anchors for a Peptides vs Classic Small-Molecule Drugs comparison.

Prednisone: Pleiotropic Corticosteroid

Prednisone is a prodrug converted hepatically to prednisolone, which binds the glucocorticoid receptor (GR) with high affinity. GR activation suppresses NF-kB and AP-1 transcription factors, producing broad anti-inflammatory effects. The word "broad" is the problem: the same receptor drives glucose dysregulation, bone density loss, and HPA-axis suppression. Prednisone exemplifies how small-molecule pleiotropism generates both therapeutic power and off-target liability.

For researchers, this is instructive. When a peptide analogue targets a single cytokine pathway, say, an IL-6 receptor-binding peptide, the mechanistic footprint is far narrower than prednisone's. Understanding how polypeptide drug mechanisms differ from classic pharmacology helps contextualize those differences in study design.

Atorvastatin: Prototypical Enzyme Inhibitor

Atorvastatin competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis. It is among the most prescribed drugs in history, demonstrating that a well-defined enzymatic target and favorable pharmacokinetics can produce durable clinical impact. Its hepatic first-pass extraction is high, concentrating drug effect in the liver and limiting systemic exposure, a pharmacokinetic feature that peptide researchers often try to replicate through tissue-targeted delivery systems.

Metabolic peptide analogues, including GLP-1 receptor agonists and MOTS-c, pursue overlapping cardiometabolic endpoints via entirely different mechanisms. The top research peptides for metabolic health illustrate how peptide-based approaches are challenging atorvastatin's territory without competing on the same receptor.

Spironolactone: Steroidal Receptor Antagonist

Spironolactone blocks the mineralocorticoid receptor (MR) to reduce aldosterone-driven sodium retention. Its steroidal scaffold, however, also antagonizes androgen and progesterone receptors, producing anti-androgenic side effects that limit use in certain populations. This cross-reactivity has spurred interest in non-steroidal MR antagonists and, separately, in peptide-based modulators that achieve aldosterone pathway interference with narrower receptor engagement.

Spironolactone's story also intersects with endocrine pharmacology more broadly. Research into how enclomiphene and related compounds interface with estrogen receptor biology provides a useful parallel for understanding receptor cross-reactivity across drug classes.

Designing Research Protocols That Compare Both Drug Classes

Designing Research Protocols That Compare Both Drug Classes

When building a comparative study, researchers must account for several variables that differ fundamentally between peptides and small molecules.

Dosing and delivery considerations:

  • Small molecules: oral gavage or dissolved in vehicle; stable at room temperature
  • Peptides: subcutaneous or intravenous injection; cold-chain storage required; reconstitution protocols critical

Stability and half-life:

Prednisone has a plasma half-life of roughly 3-4 hours; atorvastatin, approximately 14 hours. Many unmodified research peptides have half-lives under 30 minutes due to serum protease activity. Modified analogues, cyclized, PEGylated, or D-amino-acid substituted, extend stability significantly, which is why formulation choice is a study variable, not merely a logistical detail.

Selectivity profiling:

"The selectivity advantage of peptides is only realized if the researcher controls for delivery efficiency. A peptide that degrades before reaching its target is not more selective, it is simply inactive."

This principle shapes how labs approach cellular and receptor-level research using peptide mechanisms. Stability assays should precede receptor-binding assays in any rigorous protocol.

AI-assisted design in 2026:

Generative models now propose peptide sequences with predicted receptor affinity, protease resistance, and membrane permeability in silico before synthesis. For small molecules, AI-driven scaffold hopping has been standard for years. The convergence of both pipelines is reshaping how researchers select lead compounds, with hybrid peptidomimetics, molecules that combine peptide selectivity with small-molecule oral bioavailability, emerging as a major 2026 pipeline category.

Researchers evaluating mitochondria-targeted compounds should also consider how adenosine triphosphate and mitochondrial function factor into endpoint selection when comparing energy-pathway drugs across both classes.

Conclusion

The Peptides vs Classic Small-Molecule Drugs: A Researcher's Guide Using Prednisone, Atorvastatin, and Spironolactone as Case Studies framework offers a structured way to move beyond surface-level comparisons. Prednisone reveals the cost of pleiotropism; atorvastatin demonstrates the power of precise enzyme inhibition; spironolactone illustrates how receptor cross-reactivity drives the search for more selective modalities, exactly the selectivity that well-designed peptides can provide.

Actionable next steps for researchers in 2026:

  1. Map the receptor profile of your small-molecule comparator before selecting a peptide analogue, off-target overlap will confound results.
  2. Run stability assays on all peptide compounds under study conditions before committing to a dosing schedule.
  3. Use AI-generated selectivity predictions as a screening filter, not a final verdict.
  4. Consider hybrid peptidomimetic leads where oral bioavailability is a study requirement.
  5. Source research-grade compounds from verified suppliers, purity directly determines data reproducibility. Reviewing lab-tested peptides with documented certificates of analysis is a non-negotiable starting point.

The future of pharmacological research is not a contest between these two drug classes. It is a deliberate, evidence-driven choice about which tool serves each experimental question, and that choice is only possible when researchers understand both sides of the divide with equal depth.

Peptides vs Classic Small‑Molecule Drugs: How GLP-3 Retatrutide, MOTS-c, and 5-Amino-1MQ Change Lab Design Compared With Prednisone and Atorvastatin

Peptides vs Classic Small‑Molecule Drugs: How GLP-3 Retatrutide, MOTS-c, and 5-Amino-1MQ Change Lab Design Compared With Prednisone and Atorvastatin

/0 Comments/in /by

More than 100 peptide-based drugs are now in clinical development worldwide, yet most research labs were built around the chemistry of small molecules like prednisone and atorvastatin. That gap is widening fast. Understanding Peptides vs Classic Small-Molecule Drugs: How GLP-3 Retatrutide, MOTS-c, and 5-Amino-1MQ Change Lab Design Compared With Prednisone and Atorvastatin is no longer an academic exercise, it is a practical infrastructure question for every team working in metabolic disease, obesity, or longevity research in 2026.

Key Takeaways

  • Peptides like retatrutide and MOTS-c occupy a structural middle ground between small molecules and biologics, demanding specialized synthesis, stability, and PK/PD infrastructure.
  • Classic small molecules such as prednisone and atorvastatin retain strong advantages in oral delivery, cost, and membrane penetration.
  • Retatrutide is a 39-amino-acid triple agonist still in the investigational phase, with commercial launch expected in the mid-2026 to 2027 window.
  • MOTS-c is a mitochondria-derived peptide requiring metabolic stress assays not typically used in standard small-molecule labs.
  • 5-Amino-1MQ remains a preclinical NNMT-inhibiting small molecule with robust mouse data but no human trials yet.

What Separates Peptides From Small Molecules at the Bench

What Separates Peptides From Small Molecules at the Bench

The distinction starts with molecular size and structure. Small molecules, including corticosteroids like prednisone and statins like atorvastatin, typically contain fewer than 500 daltons, cross cell membranes passively, and can be formulated as oral tablets. Their synthesis is well-understood, their shelf stability is high, and standard analytical chemistry labs handle them with ease. These properties explain why small molecules remain the backbone of most early-stage drug discovery pipelines.

Peptides are fundamentally different. Ranging from roughly 10 to 50 amino acids, they are large enough to engage complex receptor surfaces with high selectivity but small enough to be synthesized in the lab rather than expressed in cell culture like antibodies. That middle-ground position comes with trade-offs: peptides are vulnerable to proteolytic degradation, prone to aggregation and fibrillation, and generally require injectable delivery. Researchers working with lab tested peptides must invest in solid-phase synthesis equipment, HPLC-based purity analytics, and cold-chain storage that a standard small-molecule lab simply does not need.

Key structural differences at a glance:

Feature Small Molecule (e.g., Atorvastatin) Peptide (e.g., Retatrutide)
Molecular weight Under 500 Da 1,000 to 5,000+ Da
Delivery route Oral Injectable (typically)
Synthesis method Organic chemistry Solid-phase peptide synthesis
Primary stability risk Oxidation, hydrolysis Proteolysis, aggregation
Receptor engagement Single target, often Multi-target possible

AI-driven drug discovery platforms now explicitly separate peptide and small-molecule design pipelines, reinforcing that the computational infrastructure required is also distinct.

Retatrutide, MOTS-c, and 5-Amino-1MQ as Case Studies in Lab Design

Retatrutide, MOTS-c, and 5-Amino-1MQ as Case Studies in Lab Design

These three compounds illustrate the full spectrum of modern metabolic drug research and the lab demands each creates.

Retatrutide: Engineering Complexity at 39 Amino Acids

Retatrutide is a 39-amino-acid triple agonist that simultaneously activates GLP-1, GIP, and glucagon receptors. Its Phase 3 obesity data set a new efficacy benchmark, and commercial launch is widely anticipated in the mid-2026 to 2027 window, though it remains investigational. Designing research programs around retatrutide requires receptor biology expertise across three distinct pathways, engineered pharmacokinetic modeling, and multi-target assay platforms. Labs accustomed to single-target small-molecule screening must expand significantly. Teams exploring study design for peptides will find that multi-agonist compounds like retatrutide demand endpoint panels that go far beyond standard lipid or glucose readouts.

MOTS-c: Mitochondrial Biology Enters the Clinic

MOTS-c is a mitochondria-derived peptide that functions as an exercise mimetic by activating AMPK and related metabolic stress pathways. It has recently entered a first registered Phase 2a human trial in prediabetes, though it remains far from approval. The critical lab implication is that MOTS-c research requires mitochondrial function assays, metabolic stress platforms, and bioenergetics readouts, none of which are standard in a classic small-molecule lab. This is a meaningful infrastructure investment, not a minor adjustment.

"Mitochondria-derived peptides like MOTS-c are forcing metabolic research labs to build assay capabilities that did not exist in most facilities five years ago."

5-Amino-1MQ: Where Small-Molecule Workflows Still Lead

5-Amino-1MQ is an NNMT (nicotinamide N-methyltransferase) inhibitor with compelling preclinical data in mouse models of obesity and metabolic dysfunction. It has no human trial data yet, and its development follows a conventional small-molecule pathway. This compound is a reminder that classic workflows, organic synthesis, cell-based NNMT activity assays, standard PK profiling, still dominate early metabolic research. For labs evaluating translational research design, 5-Amino-1MQ represents the lower-infrastructure entry point compared with peptide programs.

How Peptide Programs Reshape Lab Infrastructure Compared With Prednisone and Atorvastatin

How Peptide Programs Reshape Lab Infrastructure Compared With Prednisone and Atorvastatin

The contrast becomes sharpest when comparing active peptide programs against established small-molecule drugs. Prednisone and atorvastatin are manufactured at scale with well-documented chemistry, standard QC protocols, and oral formulations that require no cold chain. Their analytical validation is straightforward.

Peptide programs demand a different stack entirely. Solid-phase peptide synthesis units, lyophilization equipment, aggregation assays, and complex PK/PD modeling software are now baseline requirements. Stability analytics must account for fibrillation and proteolysis under physiological conditions, failure modes that simply do not apply to a statin or corticosteroid.

Core lab capability gaps when transitioning from small molecules to peptides:

  • Solid-phase synthesis and purification hardware
  • Aggregation and fibrillation detection assays
  • Proteolytic stability profiling
  • Multi-receptor binding and functional assay panels
  • Cold-chain formulation and storage infrastructure
  • Advanced PK/PD modeling for multi-agonist compounds

For teams considering study design for peptide-versus-small-molecule comparative studies, these capability gaps must be mapped before protocol development begins. Researchers sourcing compounds for preclinical work should also evaluate wholesale peptides options to manage cost at scale.

The near-term outlook is clear: peptide-centric pipelines anchored by compounds like retatrutide and MOTS-c are expanding into obesity and metabolic disease, while 5-Amino-1MQ and similar NNMT inhibitors keep the small-molecule workflow relevant for early discovery. Labs that understand Peptides vs Classic Small-Molecule Drugs: How GLP-3 Retatrutide, MOTS-c, and 5-Amino-1MQ Change Lab Design Compared With Prednisone and Atorvastatin will be better positioned to allocate resources across both paradigms.

Conclusion

The divide between peptide therapeutics and classic small-molecule drugs is not merely chemical, it is operational. Retatrutide's multi-receptor complexity, MOTS-c's mitochondrial biology, and 5-Amino-1MQ's conventional NNMT-inhibitor pathway each demand a different lab configuration, and none of them map cleanly onto the infrastructure built for prednisone or atorvastatin.

Actionable next steps for research teams in 2026:

  1. Audit current lab capabilities against the peptide-specific requirements outlined above before committing to a peptide program.
  2. Prioritize solid-phase synthesis, aggregation analytics, and multi-target assay development if retatrutide or MOTS-c analogs are in the pipeline.
  3. Retain small-molecule workflows for early NNMT-inhibitor screening and compounds like 5-Amino-1MQ where oral delivery and cost efficiency matter.
  4. Build PK/PD modeling capacity that can handle multi-agonist peptide pharmacology, single-target models are insufficient.
  5. Source compounds from verified suppliers and review translational research design frameworks before finalizing study endpoints.

Labs that plan now for peptide-centric infrastructure while maintaining small-molecule competency will be best equipped for the metabolic drug landscape taking shape through 2027 and beyond.

Peptides vs Classic Small-Molecule Drugs: How Compounds Like Prednisone, Amlodipine, and Metoprolol Differ From Modern Research-Use Peptides

Peptides vs Classic Small-Molecule Drugs: How Compounds Like Prednisone, Amlodipine, and Metoprolol Differ From Modern Research-Use Peptides

/0 Comments/in /by

{"cover":"Professional landscape format (1536×1024) hero image with bold text overlay (≤42 chars): 'Peptides vs Classic Small-Molecule Drugs' in crisp white bold sans-serif centered on a deep navy semi-transparent panel, 8% safe margins from every edge, no text touching edges. Background: split editorial scene, left side shows a clinical pharmacy shelf with amber pill bottles (prednisone, amlodipine labels), right side shows a modern research lab with peptide vials on ice and molecular chain diagrams on a lightboard. Cool blue and white color palette, magazine-quality editorial lighting, high contrast, pharmaceutical science aesthetic.","content":["Bright editorial infographic-style landscape (1536×1024): two large molecular structure illustrations side by side, left shows a compact steroid ring structure labeled 'Small Molecule' in bold 4-word label, right shows an elongated amino acid chain labeled 'Peptide Chain', both rendered as glowing 3D models on a clean white laboratory background with soft blue accent lighting. Scientific diagram aesthetic, vivid teal and orange contrast palette, no tables, no pricing grids, save-worthy Pinterest science illustration style.","Split-screen editorial photograph landscape (1536×1024): left half shows a close-up of white prednisone tablets and amlodipine capsules arranged on a stainless steel lab tray under bright clinical white lighting; right half shows research-use peptide vials (BPC-157, MOTS-c labeled in 3-word max text) on crushed ice in a modern biochemistry lab with blue LED ambient lighting. High-contrast pharmaceutical editorial photography, cool clinical palette of white, steel-blue, and amber, sharp product focus, magazine quality.","Symbolic conceptual illustration landscape (1536×1024): isometric flat-vector scene of a research laboratory interior, a female South Asian scientist in a white coat examines a glowing peptide chain hologram floating above a lab bench, while in the background a wall display shows simplified receptor-binding diagrams with short labels 'Receptor Target' and 'Signal Path'. Bright daylight through large windows, clean pastel palette of mint green, soft yellow, and white, modern scientific illustration style, no tables, no grids, Pinterest-quality editorial."]

Professional landscape hero image () with a reading "Peptides vs Classic Small-Molecule Drugs…". CRITICAL TYPOGRAPHY RULES:

More than 90% of all approved drugs on the market today are small molecules, yet the fastest-growing segment of pharmaceutical research now centers on peptides. This shift is not accidental. As researchers probe the limits of traditional pharmacology, the structural and mechanistic gap between classic drugs like prednisone, amlodipine, and metoprolol and modern research-use peptides has become one of the most important distinctions in biochemistry. Understanding peptides vs classic small-molecule drugs clarifies why compounds like BPC-157, MOTS-c, and GLP-3 occupy a fundamentally different category from the drugs most people take daily.

Key Takeaways

  • Small-molecule drugs are compact, chemically synthesized compounds that typically act on a single receptor or enzyme target.
  • Peptides are short chains of amino acids that mimic or modulate the body's own signaling molecules, enabling more targeted biological interactions.
  • Classic drugs like prednisone, amlodipine, and metoprolol have well-established clinical profiles; research-use peptides are studied under controlled laboratory conditions and are not approved for human therapeutic use.
  • Peptides generally have higher target specificity but lower oral bioavailability than small molecules.
  • The regulatory and research frameworks governing peptides differ substantially from those governing licensed pharmaceuticals.

Key Takeaways

Structural Foundations: What Separates Small Molecules From Peptides

The most fundamental difference in peptides vs classic small-molecule drugs is molecular architecture.

Small molecules, including prednisone, amlodipine, and metoprolol, are low-molecular-weight organic compounds, typically under 500 daltons. They are built through chemical synthesis, not biological processes, and their compact size allows them to cross cell membranes, enter the bloodstream via oral administration, and bind to specific receptor pockets.

Feature Small-Molecule Drugs Research-Use Peptides
Molecular weight Under 500 Da 500-5,000+ Da
Composition Synthetic organic chemistry Amino acid chains
Oral bioavailability Generally high Generally low
Synthesis route Chemical Chemical or biosynthetic
Target specificity Moderate to high High

Peptides, by contrast, are short chains of amino acids, typically 2 to 50 residues, that mimic or modulate the body's endogenous signaling molecules. Their larger size and more complex three-dimensional shape allow them to interact with biological targets in ways small molecules cannot, but this same size makes them vulnerable to digestive enzymes, which is why many research-use peptides require parenteral administration.

"The structural complexity of a peptide is both its greatest advantage and its primary delivery challenge."

Compounds like TB-500 or the BPC-157 and TB-500 combination illustrate this point well, their amino acid sequences enable highly specific tissue interactions that a small steroid molecule like prednisone simply cannot replicate.

Mechanisms of Action: How Prednisone, Amlodipine, and Metoprolol Work vs Research Peptides

Mechanisms of Action: How Prednisone, Amlodipine, and Metoprolol Work vs Research Peptides

Classic small-molecule drugs each act through well-characterized, narrow mechanisms:

  • Prednisone is a synthetic corticosteroid. It binds glucocorticoid receptors inside cells, suppressing inflammatory gene transcription broadly across multiple tissue types. Its wide receptor distribution explains both its therapeutic power and its side-effect profile (blood sugar changes, bone density loss, immune suppression).
  • Amlodipine is a calcium channel blocker. It binds L-type calcium channels in vascular smooth muscle, reducing calcium influx and causing vasodilation. The mechanism is highly localized to one channel subtype.
  • Metoprolol is a beta-1 selective adrenergic blocker. It competes with catecholamines at beta-1 receptors in cardiac tissue, slowing heart rate and reducing myocardial oxygen demand.

Each of these drugs acts on a defined, single-class receptor. Their mechanisms are predictable, well-studied, and the basis for decades of clinical data.

Research-use peptides operate differently. Rather than blocking or activating a single receptor, many peptides act as signaling modulators, they interact with receptor complexes, growth factor pathways, or intracellular signaling cascades in a more context-dependent way.

For example:

  • BPC-157 is studied for its interactions with growth hormone receptor pathways and nitric oxide systems, with research endpoints focused on tissue repair models.
  • MOTS-c is a mitochondria-derived peptide investigated for its role in metabolic regulation and cellular stress responses. Research on MOTS-c and mitochondrial function explores mechanisms that have no equivalent in classic pharmacology.
  • GLP-1 and GLP-3 class peptides act on incretin receptors involved in insulin secretion and gut motility, a mechanism that bridges peptide biology and metabolic research.

The SS-31 peptide's mitochondrial research themes demonstrate another dimension: peptides can localize to specific organelles, something small molecules rarely achieve with the same precision.

Research Context, Regulatory Status, and Practical Differences

Research Context, Regulatory Status, and Practical Differences

Understanding peptides vs classic small-molecule drugs also requires clarity on their regulatory and research contexts.

Prednisone, amlodipine, and metoprolol are FDA-approved pharmaceuticals. They have completed clinical trials, carry established dosing guidelines, and are prescribed by licensed clinicians for defined indications. Their safety and efficacy data span millions of patient-years.

Research-use peptides occupy a different category entirely. Compounds like AOD-9604 or Epithalon are sold strictly for laboratory and preclinical research purposes. They are not approved for human therapeutic use, and their research endpoints are studied in controlled in vitro and animal model settings.

Key practical distinctions include:

  • Stability: Small molecules are generally shelf-stable at room temperature. Most research peptides require refrigeration or lyophilization to maintain structural integrity.
  • Administration route: Classic drugs are predominantly oral. Research peptides are typically reconstituted and administered via injection in research settings.
  • Selectivity: Peptides often show higher target selectivity, which is why combinations like LL-37 and SS-31 are studied for their complementary, non-overlapping mechanisms.
  • Research endpoints: Small-molecule research focuses on receptor occupancy and clinical outcomes. Peptide research often examines upstream signaling, gene expression changes, and cellular repair processes.

Researchers exploring BDNF-related peptide pathways or Selank's neurological research profile encounter a level of mechanistic specificity that classic pharmacology rarely achieves.

Conclusion

The comparison of peptides vs classic small-molecule drugs is not a question of which category is superior, it is a question of purpose, mechanism, and context. Prednisone, amlodipine, and metoprolol are proven therapeutic tools with decades of clinical validation. Research-use peptides like BPC-157, MOTS-c, and GLP-3 represent a different scientific frontier: larger, more structurally complex molecules that interact with biological systems in ways that mirror the body's own signaling language.

Actionable next steps for researchers and informed readers:

  1. Review primary literature on specific peptide mechanisms before drawing comparisons to approved drugs.
  2. Source research-use peptides only from verified suppliers with documented purity testing.
  3. Consult the growing body of preclinical data on mitochondrial peptides, incretin analogs, and tissue-repair compounds to understand where the science currently stands.
  4. Recognize that regulatory status is not a proxy for scientific interest, many of the most actively studied peptides are pre-clinical compounds with significant research momentum.

The structural and mechanistic divide between small molecules and peptides will continue to shape pharmacology research well into the future.